259 related articles for article (PubMed ID: 12637486)
21. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
[TBL] [Abstract][Full Text] [Related]
22. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
Furman WL; Stewart CF; Kirstein M; Kepner JL; Bernstein ML; Kung F; Vietti TJ; Steuber CP; Becton DL; Baruchel S; Pratt C
J Clin Oncol; 2002 Mar; 20(6):1617-24. PubMed ID: 11896112
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
24. Clofarabine: a size that fits all, may not fit all.
Vij R
Leuk Lymphoma; 2009 Mar; 50(3):309-10. PubMed ID: 19347718
[No Abstract] [Full Text] [Related]
25. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
[TBL] [Abstract][Full Text] [Related]
26. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.
Aplenc R; Blaney SM; Strauss LC; Balis FM; Shusterman S; Ingle AM; Agrawal S; Sun J; Wright JJ; Adamson PC
J Clin Oncol; 2011 Mar; 29(7):839-44. PubMed ID: 21263099
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
Wilhelm M; O'Brien S; Rios MB; Estey E; Keating MJ; Plunkett W; Sorenson M; Kantarjian HM
Leuk Lymphoma; 1999 Aug; 34(5-6):511-8. PubMed ID: 10492074
[TBL] [Abstract][Full Text] [Related]
28. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Faderl S; Gandhi V; O'Brien S; Bonate P; Cortes J; Estey E; Beran M; Wierda W; Garcia-Manero G; Ferrajoli A; Estrov Z; Giles FJ; Du M; Kwari M; Keating M; Plunkett W; Kantarjian H
Blood; 2005 Feb; 105(3):940-7. PubMed ID: 15486072
[TBL] [Abstract][Full Text] [Related]
29. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ
Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
[TBL] [Abstract][Full Text] [Related]
32. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.
Gelmon K; Hirte H; Fisher B; Walsh W; Ptaszynski M; Hamilton M; Onetto N; Eisenhauer E
Invest New Drugs; 2004 Aug; 22(3):263-75. PubMed ID: 15122073
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Zeidan AM; Ricklis RM; Carraway HE; Yun HD; Greer JM; Smith BD; Levis MJ; McDevitt MA; Pratz KW; Showel MM; Gladstone DE; Gore SD; Karp JE
Br J Haematol; 2012 Jul; 158(2):198-207. PubMed ID: 22594769
[TBL] [Abstract][Full Text] [Related]
34. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
van Besien K; Stock W; Rich E; Odenike O; Godley LA; O'Donnell PH; Kline J; Nguyen V; Del Cerro P; Larson RA; Artz AS
Biol Blood Marrow Transplant; 2012 Jun; 18(6):913-21. PubMed ID: 22079470
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of temozolomide in relapsed/refractory acute leukemia.
Seiter K; Liu D; Loughran T; Siddiqui A; Baskind P; Ahmed T
J Clin Oncol; 2002 Aug; 20(15):3249-53. PubMed ID: 12149298
[TBL] [Abstract][Full Text] [Related]
37. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Faderl S; Gandhi V; Keating MJ; Jeha S; Plunkett W; Kantarjian HM
Cancer; 2005 May; 103(10):1985-95. PubMed ID: 15803490
[TBL] [Abstract][Full Text] [Related]
38. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
Kirschbaum MH; Stein AS; Popplewell L; Delioukina M; Chen R; Nakamura R; Snyder D; Conrad J; Lacey SF; Frankel P; Dagis A; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):432-40. PubMed ID: 21801703
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K; Ogawa C; Okamoto Y; Kudo K; Inagaki J; Morimoto T; Mizukami H; Ecstein-Fraisse E; Kikuta A
Int J Hematol; 2016 Aug; 104(2):245-55. PubMed ID: 27086352
[TBL] [Abstract][Full Text] [Related]
40. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Faderl S; Garcia-Manero G; Estrov Z; Ravandi F; Borthakur G; Cortes JE; O'Brien S; Gandhi V; Plunkett W; Byrd A; Kwari M; Kantarjian HM
J Clin Oncol; 2010 Jun; 28(16):2755-60. PubMed ID: 20421540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
